Abstract
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease. Recommendations for disease monitoring and treatment of recurrent disease are also included. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. This article summarizes the panel's discussions for the 2021 update of the guidelines with regard to systemic therapy for metastatic castration-resistant prostate cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 134-143 |
| Number of pages | 10 |
| Journal | JNCCN Journal of the National Comprehensive Cancer Network |
| Volume | 19 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2 2021 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Humans
- Male
- Neoplasm Metastasis
- Neoplasm Staging
- Prostatic Neoplasms, Castration-Resistant
- Prostatic Neoplasms/diagnosis
- Risk Assessment
Fingerprint
Dive into the research topics of 'Prostate cancer, version 1.2021: Prostate Cancer, Version 1.2021'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver